Pursuing
Class II FDA clearance
Next Milestone
Clinical Study 2027
WE MAKE PAIN
measurable.
To bring Pain Care to the standard we've already set for diabetes, heart disease, and every other dynamic condition.
“Medicine asks you to make perfect decisions with imperfect information.”* We strive to make that information more perfect.
*Siddhartha Mukherjee, The Laws of Medicine
The scope of the problem
25
%
Americans report chronic pain
40-80
%
Are misdiagnosed for years.
$722.8
B
The annual cost for the United States.
Because
The gold standard for pain care is still “Pick a number between 0 - 10.”
Despite the complexity of pain
Type 01
Nociceptive
Tissue Damage
Sprains, fractures, arthritis, post-surgical pain.
Type 02
Neuropathic
Nerve Damage
Spinal cord injury pain, diabetic neuropathy, post-herpetic neuralgia, sciatica.
Type 03
Nociplastic
Altered Pain Processing
Fibromyalgia, irritable bowel syndrome, many chronic low back pain cases.
Pain care reimagined
OBJECTIVE PAIN INTELLIGENCE FOR MORE ACCURATE TREATMENT + OPIOID TITRATION
TEAM
Built by engineers, clinicians, and scientists from Weill Cornell Medicine, Harvard, Pratt, Amazon, and Medtronic.
Sushir Kadidal
CEO. Engineering. Industrail Design.
Harry Sin, MBA
COO. Biomedical Engineering.
Bobak Mosadegh, PhD
CSO. Clinical Research.
ADVISORS
Dr. Rohan Jotwani, MD, MBA
Interventional Pain
JoAnn Difede, PhD
Clinical Trials
Shepard Bentley
Regulatory affairs
GET INVOLVED
CLINICIANS
Partner with us on early clinical validation.
INVESTORS
Back the first objective pain measurement platform. $1.2M pre-seed
Contact Us
NOCI
MAKING PAIN MEASURABLE
Noci Corporation. All Rights Reserved.
Pursuing
Class II FDA clearance
Next Milestone
Clinical Study 2027
WE MAKE PAIN
measurable.
To bring Pain Care to the standard we've already set for diabetes, heart disease, and every other dynamic condition.
“Medicine asks you to make perfect decisions with imperfect information.”* We strive to make that information more perfect.
*Siddhartha Mukherjee, The Laws of Medicine
The scope of the problem
25
%
Americans report chronic pain
40-80
%
Are misdiagnosed for years.
$722.8
B
The annual cost for the United States.
Because
The gold standard for pain care is still “Pick a number between 0 - 10.”
Despite the complexity of pain
Type 01
Nociceptive
Tissue Damage
Sprains, fractures, arthritis, post-surgical pain.
Type 02
Neuropathic
Nerve Damage
Spinal cord injury pain, diabetic neuropathy, post-herpetic neuralgia, sciatica.
Type 03
Nociplastic
Altered Pain Processing
Fibromyalgia, irritable bowel syndrome, many chronic low back pain cases.
Pain care reimagined
OBJECTIVE PAIN INTELLIGENCE FOR MORE ACCURATE TREATMENT + OPIOID TITRATION
TEAM
Built by engineers, clinicians, and scientists from Weill Cornell Medicine, Harvard, Pratt, Amazon, and Medtronic.
Sushir Kadidal
CEO. Engineering. Industrail Design.
Harry Sin, MBA
COO. Biomedical Engineering.
Bobak Mosadegh, PhD
CSO. Clinical Research.
ADVISORS
Dr. Rohan Jotwani, MD, MBA
Interventional Pain
JoAnn Difede, PhD
Clinical Trials
Shepard Bentley
Regulatory affairs
GET INVOLVED
CLINICIANS
Partner with us on early clinical validation.
INVESTORS
Back the first objective pain measurement platform. $1.2M pre-seed
Contact Us
NOCI
MAKING PAIN MEASURABLE
Noci Corporation. All Rights Reserved.
Pursuing
Class II FDA clearance
Next Milestone
Clinical Study 2027
WE MAKE PAIN
measurable.
To bring Pain Care to the standard we've already set for diabetes, heart disease, and every other dynamic condition.
“Medicine asks you to make perfect decisions with imperfect information.”* We strive to make that information more perfect.
*Siddhartha Mukherjee, The Laws of Medicine
The scope of the problem
25
%
Americans report chronic pain
40-80
%
Are misdiagnosed for years.
$722.8
B
The annual cost for the United States.
Because
The gold standard for pain care is still “Pick a number between 0 - 10.”
Despite the complexity of pain
Type 01
Nociceptive
Tissue Damage
Sprains, fractures, arthritis, post-surgical pain.
Type 02
Neuropathic
Nerve Damage
Spinal cord injury pain, diabetic neuropathy, post-herpetic neuralgia, sciatica.
Type 03
Nociplastic
Altered Pain Processing
Fibromyalgia, irritable bowel syndrome, many chronic low back pain cases.
Pain care reimagined
OBJECTIVE PAIN INTELLIGENCE FOR MORE ACCURATE TREATMENT + OPIOID TITRATION
TEAM
Built by engineers, clinicians, and scientists from Weill Cornell Medicine, Harvard, Pratt, Amazon, and Medtronic.
Sushir Kadidal
CEO. Engineering. Industrial Design.
Harry Sin, MBA
COO. Biomedical Engineering.
Bobak Mosadegh, PhD
CSO. Clinical Research.
ADVISORS
Dr. Rohan Jotwani, MD, MBA
Interventional Pain
JoAnn Difede, PhD
Clinical Trials
Shepard Bentley
Regulatory affairs
GET INVOLVED
CLINICIANS
Partner with us on early clinical validation.
INVESTORS
Back the first objective pain measurement platform. $1.2M pre-seed
Contact Us
NOCI
MAKING PAIN MEASURABLE
Noci Corporation. All Rights Reserved.